Stock Analysis on Net
AI Tokens
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Common-Size Income Statement
Quarterly Data

Boston Scientific Corp., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018
Net sales 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of products sold -30.69 -31.15 -30.88 -31.17 -31.56 -31.08 -30.70 -30.71 -32.49 -36.89 -32.68 -39.49 -31.69 -29.27 -28.70 -28.81 -29.28 -28.43 -28.12 -29.68 -28.25
Gross profit 69.31% 68.85% 69.12% 68.83% 68.44% 68.92% 69.30% 69.29% 67.51% 63.11% 67.32% 60.51% 68.31% 70.73% 71.30% 71.19% 70.72% 71.57% 71.88% 70.32% 71.75%
Selling, general and administrative expenses -35.82 -35.87 -35.71 -35.88 -35.03 -36.87 -36.36 -36.43 -36.99 -37.96 -37.01 -39.84 -38.46 -37.60 -37.38 -36.79 -34.86 -37.25 -36.36 -35.54 -36.19
Research and development expenses -9.94 -10.18 -10.69 -10.33 -10.54 -10.23 -10.57 -9.68 -10.03 -10.56 -11.85 -12.08 -11.80 -10.61 -11.30 -10.64 -11.23 -11.25 -12.08 -11.04 -10.97
Royalty expense -0.32 -0.40 -0.35 -0.34 -0.40 -0.35 -0.48 -0.39 -0.44 -0.48 -0.45 -0.40 -0.47 -0.59 -0.55 -0.65 -0.64 -0.70 -0.71 -0.68 -0.76
Amortization expense -5.99 -6.14 -6.37 -6.29 -6.54 -6.14 -6.28 -5.85 -6.72 -7.16 -7.41 -9.84 -7.90 -6.89 -6.58 -6.12 -6.42 -6.36 -6.18 -5.90 -5.93
Goodwill impairment charges 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Intangible asset impairment charges 0.00 0.00 -3.94 -0.22 0.00 -6.30 -4.37 -1.46 0.00 -0.33 -8.24 -1.70 -7.79 -0.03 0.00 -1.41 -2.69 0.00 0.00 -1.37 -0.04
Contingent consideration net (expense) benefit -0.35 1.02 -0.63 -1.11 -0.40 0.61 0.89 2.76 0.22 -0.07 -0.23 0.00 4.25 0.86 -0.30 -0.38 1.12 0.35 0.54 0.16 -0.21
Restructuring charges -0.59 -0.15 -0.13 -0.34 -0.13 -0.74 -0.31 -0.10 -0.18 -1.29 -0.11 -0.20 -0.39 -0.96 -0.11 -0.04 -0.24 -0.59 -0.13 -0.20 -0.55
Litigation-related net (charges) credits 0.00 -4.04 0.00 -1.29 0.00 -4.09 0.00 -9.68 -0.15 -0.70 -9.74 0.00 0.00 -7.68 -0.92 -0.57 5.94 -3.32 -0.75 0.00 0.00
Gain (loss) on disposal of businesses and assets 0.00 -0.68 0.00 0.00 0.00 0.96 1.36 0.06 0.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating expenses -53.02% -56.45% -57.82% -55.80% -53.04% -63.16% -56.11% -60.77% -54.07% -61.26% -75.03% -64.05% -62.56% -63.50% -57.15% -56.59% -49.02% -59.12% -55.66% -54.58% -54.64%
Operating income (loss) 16.29% 12.40% 11.29% 13.04% 15.40% 5.76% 13.20% 8.51% 13.44% 1.85% -7.71% -3.54% 5.74% 7.23% 14.15% 14.60% 21.70% 12.46% 16.21% 15.74% 17.11%
Interest expense -1.92 -1.97 -1.99 -1.97 -9.22 -2.78 -2.93 -2.79 -2.98 -3.55 -3.23 -4.54 -3.46 -6.20 -3.51 -3.38 -4.37 -2.54 -2.42 -2.29 -2.56
Other, net -1.27 1.76 -1.58 -0.43 -1.02 0.83 6.21 -0.88 1.34 13.04 2.41 -0.95 -1.42 -1.24 -7.28 -5.70 1.00 1.64 5.27 0.48 -0.97
Other income (expense) -3.19% -0.22% -3.56% -2.40% -10.24% -1.95% 3.27% -3.67% -1.64% 9.49% -0.83% -5.49% -4.88% -7.44% -10.79% -9.08% -3.37% -0.90% 2.84% -1.81% -3.53%
Income (loss) before income taxes 13.10% 12.18% 7.73% 10.64% 5.16% 3.81% 16.47% 4.84% 11.81% 11.34% -8.54% -9.04% 0.87% -0.21% 3.36% 5.51% 18.33% 11.56% 19.06% 13.94% 13.58%
Income tax (expense) benefit -3.84 -7.87 -1.80 -2.62 -1.52 -0.77 -2.18 1.20 0.58 -3.62 2.71 1.70 -0.43 137.81 1.29 0.34 -1.32 3.51 -1.00 8.35 -1.05
Net income (loss) 9.27% 4.32% 5.93% 8.01% 3.64% 3.04% 14.29% 6.04% 12.39% 7.72% -5.83% -7.34% 0.43% 137.60% 4.65% 5.85% 17.01% 15.07% 18.05% 22.29% 12.53%
Preferred stock dividends -0.41 -0.46 -0.44 -0.43 -0.43 -0.45 -0.48 -0.45 -0.51 -0.48 -0.53 -0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net income (loss) available to common stockholders 8.85% 3.86% 5.49% 7.58% 3.21% 2.59% 13.81% 5.59% 11.88% 7.24% -6.36% -7.64% 0.43% 137.60% 4.65% 5.85% 17.01% 15.07% 18.05% 22.29% 12.53%

Based on: 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31).

An analysis of the common-size income statement reveals a period of significant operational volatility centered around 2020, followed by a trend toward stabilization and recovery. While core gross margins remained relatively resilient, the bottom line was heavily influenced by non-recurring impairment charges, litigation expenses, and significant tax anomalies.

Gross Profitability Trends
Gross profit margins exhibited a high degree of stability between 70% and 72% from early 2018 through late 2019. A notable contraction occurred in 2020, reaching a low of 60.51% in June 2020. Following this period, a steady recovery is observed, with margins returning to 69.31% by March 2023, indicating a restoration of cost-of-sales efficiency.
Operating Expense Structure
Selling, general, and administrative (SG&A) expenses remained relatively consistent, generally fluctuating between 34% and 39% of net sales. Research and development (R&D) expenditures showed similar stability, typically ranging from 9.6% to 12% of net sales. This suggests a disciplined approach to maintaining operational overhead and investment in innovation relative to revenue growth.
Impact of Non-Recurring Charges
The operating income was significantly impacted by intermittent non-recurring items. Intangible asset impairment charges peaked in 2020 and 2021, with specific spikes of -7.79% and -8.24% in early and late 2020. Furthermore, litigation-related charges created substantial volatility, notably in September 2020 (-9.74%) and June 2021 (-9.68%), which contributed to temporary operating losses.
Operating Income and Net Profitability
Operating income margins transitioned from a stable range of 12% to 21% (2018-2019) to negative territory in mid-2020, hitting a low of -7.71% in September 2020. By March 2023, operating income recovered to 16.29%. Net income figures were highly distorted by a massive tax benefit in December 2019, resulting in a net income of 137.60% of sales. Excluding this anomaly, net income generally mirrors the recovery of operating income, stabilizing between 4% and 9% in the most recent periods.
Financial Obligations and Other Income
Interest expenses as a percentage of net sales were generally stable around 2% to 4%, though a spike to -9.22% occurred in March 2022. Preferred stock dividends became a consistent factor starting in mid-2020, averaging approximately 0.4% to 0.5% of net sales.

AI Ask an analyst for more

My previous chats

Add tokens

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?